Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VACTICOV2: Effect of COVID-19 Vaccination on Monocyte ROS Production
NCT05655351Phase 1Completed
- Sponsor
- CHU Nîmes
- Start
- Dec 2022
- Primary completion
- Jul 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LVRNA021 in coronavirus disease 2019 (COVID-19), sponsored by CHU Nîmes. Primary endpoint: Monocyte production of oxygenated derivatives (Reactive oxygen species) at Day 28. Started Dec 2022; status: completed.
02
Drugs
LVRNA021
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05655351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05655351.